These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 17507219)
21. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design. Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949 [TBL] [Abstract][Full Text] [Related]
22. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933 [TBL] [Abstract][Full Text] [Related]
23. Amino acid derivatives as histone deacetylase inhibitors. Hubbs JL; Zhou H; Kral AM; Fleming JC; Dahlberg WK; Hughes BL; Middleton RE; Szewczak AA; Secrist JP; Miller TA Bioorg Med Chem Lett; 2008 Jan; 18(1):34-8. PubMed ID: 18042381 [TBL] [Abstract][Full Text] [Related]
24. Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors. Angibaud P; Arts J; Van Emelen K; Poncelet V; Pilatte I; Roux B; Van Brandt S; Verdonck M; De Winter H; Ten Holte P; Marien A; Floren W; Janssens B; Van Dun J; Aerts A; Van Gompel J; Gaurrand S; Queguiner L; Argoullon JM; Van Hijfte L; Freyne E; Janicot M Eur J Med Chem; 2005 Jun; 40(6):597-606. PubMed ID: 15922843 [TBL] [Abstract][Full Text] [Related]
25. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors. Yan C; Xiu Z; Li X; Li S; Hao C; Teng H Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905 [TBL] [Abstract][Full Text] [Related]
26. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents. Oanh DT; Hai HV; Park SH; Kim HJ; Han BW; Kim HS; Hong JT; Han SB; Hue VT; Nam NH Bioorg Med Chem Lett; 2011 Dec; 21(24):7509-12. PubMed ID: 22036991 [TBL] [Abstract][Full Text] [Related]
27. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Wise LD; Turner KJ; Kerr JS Birth Defects Res B Dev Reprod Toxicol; 2007 Feb; 80(1):57-68. PubMed ID: 17294457 [TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors. Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205 [TBL] [Abstract][Full Text] [Related]
29. Structural biasing elements for in-cell histone deacetylase paralog selectivity. Wong JC; Hong R; Schreiber SL J Am Chem Soc; 2003 May; 125(19):5586-7. PubMed ID: 12733869 [TBL] [Abstract][Full Text] [Related]
31. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213 [TBL] [Abstract][Full Text] [Related]
32. Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity. Zubia A; Ropero S; Otaegui D; Ballestar E; Fraga MF; Boix-Chornet M; Berdasco M; Martinez A; Coll-Mulet L; Gil J; CossÃo FP; Esteller M Oncogene; 2009 Mar; 28(11):1477-84. PubMed ID: 19169274 [TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitors: development as cancer therapy. Marks PA; Richon VM; Kelly WK; Chiao JH; Miller T Novartis Found Symp; 2004; 259():269-81; discussion 281-8. PubMed ID: 15171260 [TBL] [Abstract][Full Text] [Related]
34. Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors. Nishino N; Jose B; Shinta R; Kato T; Komatsu Y; Yoshida M Bioorg Med Chem; 2004 Nov; 12(22):5777-84. PubMed ID: 15498654 [TBL] [Abstract][Full Text] [Related]
35. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424 [TBL] [Abstract][Full Text] [Related]
36. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Marks PA; Breslow R Nat Biotechnol; 2007 Jan; 25(1):84-90. PubMed ID: 17211407 [TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227 [TBL] [Abstract][Full Text] [Related]
38. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Faraco G; Pancani T; Formentini L; Mascagni P; Fossati G; Leoni F; Moroni F; Chiarugi A Mol Pharmacol; 2006 Dec; 70(6):1876-84. PubMed ID: 16946032 [TBL] [Abstract][Full Text] [Related]